PMAM
ADMA icon

Picton Mahoney Asset Management’s ADMA Biologics ADMA Stock Holding History

Picton Mahoney Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-780,000
Closed -$11.4M – 1203
2025
Q3 		$11.4M Buy
+780,000
New +$13.4M 0.1% 176

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Picton Mahoney Asset Management's ADMA Position: Q1 2026 in Review

Picton Mahoney Asset Management reduced its ADMA Biologics (ADMA) stake by 100% in Q1 2026, selling an estimated $3.64M and leaving 64 shares worth $577. The position accounts for ﹤0.01% of the portfolio, ranked #1225.

Picton Mahoney Asset Management first reported a position in ADMA in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.97M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Picton Mahoney Asset Management held 64 shares of ADMA Biologics worth $577 as of Q1 2026.
  • Picton Mahoney Asset Management sold 230,752 ADMA Biologics shares in Q1 2026, an estimated $3.64M.
  • ADMA Biologics made up ﹤0.01% of Picton Mahoney Asset Management's portfolio in Q1 2026, its #1225 holding.
  • Picton Mahoney Asset Management first reported a position in ADMA Biologics in Q3 2024 and has held it in 7 quarters since.
  • Picton Mahoney Asset Management's ADMA Biologics position peaked at $7.97M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.